🔎 Trials Near Me

Utama › Kanser Payudara › Nebraska › Omaha

Kajian klinikal Kanser Payudara di Omaha, NE

22 kajian untuk Kanser Payudara sedang mencari peserta di lokasi dalam dan sekitar Omaha (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Mengambil pesertaFasa 3
  • Nebraska Cancer Specialists, Omaha
Umur 18 hingga 100 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05827081

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Mengambil pesertaFasa 3
  • Research Site, Omaha
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07205822

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • Alegent Health Immanuel Medical Center, Omaha
  • Alegent Health Bergan Mercy Medical Center, Omaha
  • Alegent Health Lakeside Hospital, Omaha
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Mengambil pesertaFasa 2
  • Nebraska Cancer Specialists, Omaha
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07102381

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Mengambil pesertaFasa 2
  • Oncology Hematology West, Pc Dba Nebraska Cancer Specialists, Omaha
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07007559

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Mengambil pesertaFasa 3
  • Paradigm Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07173751

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Mengambil pesertaFasa 1/2
  • Nebraska Cancer Specialists, Omaha
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07109726

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Mengambil pesertaFasa 3
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy, Omaha
  • University of Nebraska Medical Center, Omaha
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06492616

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Mengambil pesertaFasa 3
  • Nebraska Cancer Specialists, Omaha
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06982521

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Mengambil pesertaFasa 3
  • Nebraska Medicine-Village Pointe, Omaha
  • Alegent Health Immanuel Medical Center, Omaha
  • Alegent Health Bergan Mercy Medical Center, Omaha
  • dan 3 lagi
Umur 18 hingga 60 · Wanita · Dikemas kini 2 Sep 2026 · NCT05879926

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Mengambil pesertaFasa 3
  • Nebraska Cancer Specialists, Omaha
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06072612

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

Mengambil pesertaFasa 1
  • Nebraska Cancer Specialists, Omaha
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT07660055

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Mengambil pesertaFasa 3
  • Nebraska Cancer Specialists, Omaha
  • Nebraska Medicine - University of Nebraska Medical Center, Omaha
Umur 18 hingga 100 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT05232916

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Mengambil pesertaFasa 2
  • Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
Umur 8 ke atas · Semua jantina · Dikemas kini 27 Jul 2026 · NCT05503797

Integrated Cancer Repository for Cancer Research

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • Methodist Estabrook Cancer Center, Omaha
  • Nebraska Methodist Health System, Omaha
  • University of Nebraska Medical Center, Omaha
  • dan 1 lagi
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Mengambil pesertaFasa 1
  • Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
  • XCancer Omaha / Urology Cancer Center, Omaha
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Jun 2026 · NCT05283330

ERAS Protocols in Breast Conserving Surgery

Mengambil peserta
  • University of Nebraska Medical Center, Omaha
Umur 19 ke atas · Semua jantina · Dikemas kini 19 Mei 2026 · NCT06938581

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Mengambil pesertaFasa 3
  • Nebraska Medicine-Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
  • Nebraska Medicine-Bellevue, Bellevue · 9 mi jauh
Umur 50 hingga 70 · Semua jantina · Dikemas kini 23 Apr 2026 · NCT04852887

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Mengambil pesertaKajian pemerhatian
  • Massive Bio SYNERGY-AI site, Omaha
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

Mengambil pesertaFasa 1
  • Biotheryx Investigative Site, Omaha
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Jun 2025 · NCT06515470

CtDNA Based MRD Testing for NAC Monitoring in TNBC

Mengambil pesertaKajian pemerhatian
  • Nebraska Methodist, Omaha
Umur 18 ke atas · Wanita · Dikemas kini 7 Jan 2025 · NCT06230185

Kajian Kanser Payudara di bandar lain

Kajian lain di Omaha

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.